Picture of RegenETP, logo

RGTPQ — RegenETP, News Story

0.000.00%
us flag iconLast trade - 00:00
FinancialsHighly SpeculativeMicro Cap

PolarityTE Inc expected to post a loss of 9  cents a share - Earnings Preview

* PolarityTE Inc  PTE.OQ   PTE.O  is expected to show a fall
in
quarterly revenue when it reports  results on March 30. 
    * The Salt Lake City Utah-based  company is expected to
report  a
77.9% decrease in revenue to $792.33 thousand from $3.59 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for PolarityTE Inc is
for a
loss of 9 cents per share. For the same quarter last year, the
company reported a loss of 26 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PolarityTE
Inc is
$2.25​, above​ its last closing price of $0.31. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.10       -0.12      -0.01     Beat    91.4
 Jun. 30 2021  -0.09       -0.10      -0.04     Beat    58.6
 Mar. 31 2021  -0.13       -0.12      -0.16     Missed  -37.1​
 Dec. 31 2020  -0.23       -0.16      -0.26     Missed  -57.6
 ​​Sep.        -0.20       -0.21      -0.18     Beat    12.6
 30 2020                                                
 Jun. 30 2020  -0.35       -0.38      -0.33     Beat    12.4​
 Mar. 31 2020  -0.49       -0.52      -0.53     Missed  -2.5
 Dec. 31 2019  -0.83       -0.90      -0.76     Beat    15.3
 This summary was machine generated March 28 at 13:08 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on RegenETP,

See all news